IDEAYA Biosciences, Inc. (IDYA) Latest Company News

Nov 3, 2026, 13:26 UTC
IDEAYA Biosciences reported a quarterly loss of $1.22 per share, compared with a loss of $1.26 per share expected and earnings of $1.33 per share a year earlier.
Source:
- zacks.com
Nov 3, 2026, 11:00 UTC
IDEAYA Biosciences, Inc. reported third-quarter 2026 financial results and said it had $1.15 billion in cash, cash equivalents and marketable securities as of September 30, 2026.
Source:
- prnewswire.com
Oct 23, 2026, 10:00 UTC
IDEAYA Biosciences, Inc. said it is targeting two Phase 3 registrational trials of IDE849 in extensive-stage small cell lung cancer and neuroendocrine carcinomas following successful Type C meetings with the U.S. FDA.
Source:
- prnewswire.com
Oct 23, 2026, 10:00 UTC
IDEAYA Biosciences, Inc. reported updated Phase 1 results for IDE849 in relapsed small cell lung cancer and neuroendocrine carcinomas, including median overall survival of 17.4 months in second-line SCLC and 14.7 months in second-line or later SCLC.
Source:
- prnewswire.com
Sep 28, 2026, 10:00 UTC
IDEAYA Biosciences promoted Dr. Michael White from Chief Scientific Officer to President, Research and Development, effective September 28, 2026.
Source:
- prnewswire.com
Aug 19, 2026, 10:00 UTC
IDEAYA Biosciences entered into a clinical collaboration with Genentech to evaluate IDE892 in combination with RG6620 in MTAP-deleted, KRAS G12D-mutant pancreatic ductal adenocarcinoma, with Genentech sponsoring the trial and joint governance overseeing the study.
Source:
- prnewswire.com
Aug 4, 2026, 10:00 UTC
IDEAYA Biosciences reported financial results for the second quarter ended June 30, 2026, with cash and marketable securities of approximately $1.24 billion as of that date.
Source:
- prnewswire.com
Jun 15, 2026, 10:00 UTC
IDEAYA Biosciences initiated a Phase 1/2 clinical combination study for its IDE892 MTA-Cooperative PRMT5 inhibitor in MTAP-deleted pancreatic and lung cancers.
Jun 10, 2026, 20:05 UTC
IDEAYA Biosciences closed an underwritten public offering of 7,222,225 shares of common stock and pre-funded warrants to purchase 5,555,576 shares of common stock.
Source:
- prnewswire.com
Jun 8, 2026, 20:01 UTC
IDEAYA Biosciences announced a proposed public offering of up to $300 million of common stock and pre-funded warrants.
Source:
- prnewswire.com
- prnewswire.com
Jun 3, 2026, 10:00 UTC
IDEAYA Biosciences entered into a clinical collaboration with Roche to evaluate IDE892 in combination with RG6505 for MTAP-deleted RAS-mutant pancreatic cancer.
Source:
- prnewswire.com

IDYA

IDEAYA Biosciences reported a quarterly loss of $1.22 per share, compared with a loss of $1.26 per share expected and earnings of $1.33 per share a year earlier.

IDEAYA Biosciences, Inc. reported third-quarter 2026 financial results and said it had $1.15 billion in cash, cash equivalents and marketable securities as of September 30, 2026.

IDEAYA Biosciences, Inc. said it is targeting two Phase 3 registrational trials of IDE849 in extensive-stage small cell lung cancer and neuroendocrine carcinomas following successful Type C meetings with the U.S. FDA.

IDEAYA Biosciences, Inc. reported updated Phase 1 results for IDE849 in relapsed small cell lung cancer and neuroendocrine carcinomas, including median overall survival of 17.4 months in second-line SCLC and 14.7 months in second-line or later SCLC.

IDEAYA Biosciences promoted Dr. Michael White from Chief Scientific Officer to President, Research and Development, effective September 28, 2026.

IDEAYA Biosciences entered into a clinical collaboration with Genentech to evaluate IDE892 in combination with RG6620 in MTAP-deleted, KRAS G12D-mutant pancreatic ductal adenocarcinoma, with Genentech sponsoring the trial and joint governance overseeing the study.

IDEAYA Biosciences reported financial results for the second quarter ended June 30, 2026, with cash and marketable securities of approximately $1.24 billion as of that date.

IDEAYA Biosciences initiated a Phase 1/2 clinical combination study for its IDE892 MTA-Cooperative PRMT5 inhibitor in MTAP-deleted pancreatic and lung cancers.

IDEAYA Biosciences closed an underwritten public offering of 7,222,225 shares of common stock and pre-funded warrants to purchase 5,555,576 shares of common stock.

IDEAYA Biosciences announced a proposed public offering of up to $300 million of common stock and pre-funded warrants.

IDEAYA Biosciences entered into a clinical collaboration with Roche to evaluate IDE892 in combination with RG6505 for MTAP-deleted RAS-mutant pancreatic cancer.